A Phase 2 study of WEE1 Inhibition with AZD1775 alone or combined with Cytarabine in Patients with advanced Acute Myeloid Leukemia Myelodysplastic Syndrome and Myelofibrosis

Brief description of study

The purpose of this research study is to test the safety and efficacy of an investigational drug, AZD1775 and find out what effects good and/or bad, AZD1775 alone or in combination with AraC (Cytarabine) has on you. The study drug AZD1775 is investigational, which means it is not approved by the U.S. Food & Drug Administration (FDA) to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myelofibrosis (PMF/ MF).


Clinical Study Identifier: s17-01816
ClinicalTrials.gov Identifier: NCT03718143
Principal Investigator: Raoul Tibes
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.